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Lifestyle, diabetes, and cardiovascular risk factors 10 years after bari-
atric surgery
Sjöström L, Lindroos A-K, Peltonen M, and The Swedish Obese Subjects
Study Scientific Group. N Engl J Med 2004;351:2683-93.
Conclusion: Bariatric surgery, when compared with conventional obe-
sity therapy, provides better long-term weight loss, improved lifestyle, and
amelioration of cardiovascular risk factors, with the exception of hypercho-
lesterolemia.
Summary: The Swedish Obese Subjects Study is a prospective investi-
gation involving obese subjects who underwent bariatric surgery or conven-
tional treatment for obesity. This report documents follow-up data for
subjects (mean age, 48 years; mean body mass index, 41 kg/m2) who were
enrolled in the study for at least 2 years (4047 subjects) or 10 years (1703
subjects). The follow-up rate for laboratory examinations was 86.6% at 2
years and 74.5% at 10 years.
After 2 years of follow-up, weight increased 0.1% in the control group
and decreased 23.4% in the surgery group (P .001). After 10 years, weight
had increased by 1.6% in the control group and had decreased by 16.1% in
the surgery group (P  .001). There were proportionally more physically
active subjects in the surgery group than in the control group throughout
the observation period. Two- to 10-year recovery rates from hypertriglycer-
idemia, low levels of high-density lipoprotein cholesterol, diabetes, hyper-
tension, and hyperuricemia were more favorable in the surgery than the
control group. There were no differences in recovery from hypercholester-
olemia in the control and surgery groups. The surgery group had lower 2-
and 10-year incidence rates of diabetes, hypertriglyceridemia, and hyperuri-
cemia than the control group. There were no differences between the groups
in the incidence of hypercholesterolemia and hypertension.
Comment: This was not a randomized study. The data, however,
strongly implicate bariatric surgery as an effective means of improving
cardiovascular risk factors in the morbidly obese. The study does not tell us
whether progression of established vascular disease in the morbidly obese
can be slowed by bariatric surgery. We are not currently at the point where
we can recommend bariatric surgery as a treatment to slow progression of
peripheral vascular disease. However, in patients with established cardiovas-
cular risk factors who are morbidly obese, bariatric surgery can be recom-
mended to diminish these risk factors and improve lifestyle.
Subintimal angioplasty in the treatment of patients with intermittent
claudication: Long-term results
Florenes T, Bay D, Sandbaek G, et al. Eur J Vasc Endovasc Surg 2004;28:
645-50.
Conclusion: Subintimal angioplasty should be the primary treatment
for patients with intermittent claudication when medical treatment alone has
been unsatisfactory.
Summary: The authors report the results of subintimal angioplasty
used for treatment of patients with intermittent claudication. The authors
performed 116 subintimal angioplasties in 104 patients from February 1997
to January 2000. The authors calculated primary assisted patency rates for
successful angioplasties, as well as calculated primary assisted patency rates,
on an intention-to-treat basis. Univariant and multivariant Cox regression
analysis was used to evaluate correlations of patency with comorbidities,
occlusion length, and runoff.
Technical success was achieved in 87% (n 101) of cases. There was no
early mortality. On an attention-to-treat basis (116 cases), primary assisted
patency at 6, 12, 36, and 60 months was 69%, 62%, 57%, and 54%,
respectively. In successfully recanalized cases (101 cases), primary assisted
patency at 6, 12, 36, and 60 months was 79%, 70%, 66%, and 64%. The risk
of reocclusion was related to length of occlusion, age, and male sex.
Periprocedural complications included seven hematomas, one requiring
surgical evacuation, and six perforations that did not require intervention.
Comment: The patency results in this study are reasonable, but overall
the paper is not all that helpful. We already know that subintimal angioplasty
can be successful. The goal of treatment in patients with intermittent
claudication, however, is improvement in walking and quality of life. The
authors do not even present hemodynamic data, much less data regarding
walking and quality of life. In a prospective study of treatment for intermit-
tent claudication, more functional data, and not just simple patency analysis,
should be included.
Risk of acute myocardial infarction and sudden cardiac death in pa-
tients treated with cyclo-oxygenase 2 selective and non-selective non-
steroidal inflammatory drugs: Nested case-control study
Graham DJ, Campen D, Hui R, et al. Lancet Online Publication, January
25, 2005
Conclusion: Compared with celecoxib, rofecoxib increases the risk of
serious coronary heart disease. Naproxen does not offer a protective effect
against coronary heart disease.
Summary: The Vioxx Gastrointestinal Outcomes Research Trial
(VIGOR) raised questions about the cardiovascular risk of COX-2–selective
drugs. In this trial, there was a fivefold difference in the incidence of acute
myocardial infarction in patients treated with rofecoxib 50 mg/d and
naproxen 1000 mg/d. There was no placebo group in this trial; therefore,
findings could suggest adverse effects of coxibs in general, an adverse effect
of rofecoxib, or a previously unrecognized protective effect of naproxen. The
authors sought to establish whether cardiovascular risk was increased with
rofecoxib at standard or high doses in comparison to remote nonsteroidal
anti-inflammatory drug (NSAID) use or celecoxib. Celecoxib was chosen as
a comparison drug to rofecoxib because celecoxib was the most common
alternative to rofecoxib.
This was a nested case-control study. Data were derived from Kaiser
Permanente in California. The authors assembled a cohort of all patients
aged 18 to 84 years treated with NSAIDs between January 1, 1999, and
December 31, 2001. Cases of serious coronary heart disease (defined as
acute myocardial infarction and cardiac death) were risk-set–matched for
age, sex, and health plan region. There were four controls for each case. The
authors compared current exposure to COX-2–selective and –nonselective
NSAIDS and to remote exposure to any NSAID. Rofecoxib was also
compared with celecoxib.
There were 2,302,029 person-years of follow-up. There were 8143
cases of serious coronary heart disease, 27.1% (n  2210) of which were
fatal. Multivariant adjusted odds ratios vs celecoxib were as follows: for
rofecoxib (any dose), 1.59 (95% CI, 1.1-2.32; P  .015); for rofecoxib 25
mg/d or less, 1.47 (95% CI, 0.99-2.17; P .054); and for rofecoxib greater
than 25 mg/d, 3.58 (95% CI, 1.27-10.11; P .016). For naproxen vs past
NSAID use, the adjusted odds ratio was 1.14 (95% CI, 1.00-1.30; P .05).
Comment: Parts of this article were first posted on the US Food and
Drug Administration (FDA) Web site on November 2, 2004. At that point,
the document was considered preliminary and was a source of great contro-
versy within the FDA. It is important to recognize that the current docu-
ment represents the opinion of the authors and not necessarily that of the
FDA and that the FDA did not participate in the study design, data
collection, analysis, or writing of this report. This study, however, obviously
has enormous implications for the entire class of COX-2 inhibitors and the
mechanisms of oversight used by the FDA.
Randomized clinical trial of intraoperative autotransfusion in surgery
for abdominal aortic aneurysm
Mercer KG, Spark JI, Berridge DC, et al. Br J Surg 2004;91:1443-8.
Conclusion: Autotransfusion effectively reduces the need for homol-
ogous blood transfusion (HBT) during repair of abdominal aortic aneurysm
(AAA). Use of autotransfusion was associated with a reduced incidence of
both the systemic inflammatory response syndrome (SIRS) and postopera-
tive infectious complications.
Summary: This was a randomized, single-center clinical trial of intra-
operative autotransfusion in patients undergoing repair of AAA. There were
40 patients randomized to intraoperative autotransfusion and 41 patients
who underwent surgery for AAA with homologous blood transfusion alone.
Patients in both groups received, when necessary, HBT to maintain hemo-
globin levels8 g/dL. Comparisons were made among transfusion require-
ments, the incidence of infection, and the incidence of SIRS between the
two groups.
Fewer patients in the intraoperative autotransfusion group required
HBT (21 vs 31; P  .038). The median blood requirement per patient was
two units lower in the patients undergoing intraoperative autotransfusion vs
those treated with HBT alone (P  .012). There was a higher incidence of
SIRS (20 vs 9 patients; P  .020) and a higher incidence of chest infection
(12 vs 4 patients; P  .049) in the HBT-alone group. The risk of SIRS was
related to aortic cross-clamp time in the intraoperative autotransfusion
group only.
Comment: The author’s finding that intraoperative autotransfusion is
associated with reduced postoperative infection is consistent with observa-
tional studies linking a diminished immunologic response to HBT. The
911
mechanism of this potential decrease in immunologic competence with
HBT is unknown. The observation, however, provides another reason, in
addition to those of conserving blood bank resources and diminishing direct
bloodborne infections, for use of intraoperative autotransfusion.
Histological correlates of carotid plaque surface morphology on lumen
contrast imaging
Lovett JK, Gallagher PJ, Hands LJ, et al. Circulation 2004;110:2190-7.
Conclusion: There are strong associations between detailed histologic
analysis and carotid angiographic plaque surface morphology. Surface mor-
phology on carotid angiography is a highly sensitive marker of plaque
instability.
Summary: Studies comparing angiographic plaque surface morphol-
ogy and carotid plaque pathology have been small and unblinded. Most have
assessed only the macroscopic appearance of the plaque. The authors per-
formed a large study comparing angiographic surface morphology with
detailed histologic analysis of the plaque.
On the basis of conventional selective carotid arteriograms in patients
undergoing endarterectomy for severe symptomatic stenosis, carotid plaque
surface morphology was classified as irregular, smooth, or ulcerated. There
were 128 selective arteriographic studies included in this study. Angio-
graphic assessment was blinded and was compared with 10 histologic
features recorded on detailed microscopy of the plaque. These features were
recorded by using reproducible semiquantitative scales.
Ulceration on angiography was associated with plaque rupture (P 
.001), a large lipid core (P  .005), intraplaque hemorrhage (P  .001),
decreased fibrous tissue (P  .003), and increased overall instability (P 
.001). Ulcerated plaques on angiography were more likely than smooth
plaques to be ruptured (OR 15.4, 95% CI 2.7-87.3, P 0.001), show
a large lipid core (OR  26.7, 95% CI  2.6-270, P  0.001), or have a
large intraplaque hemorrhage (OR  17.0, 95% CI  2.0-147, P  0.02).
Comment: This is the largest study to compare plaque histology with
angiographic surface morphology. That angiographic features of irregularity
and ulceration predict histologic features of unstable plaques suggests that
assessment of the plaque surface by contrast studies may be useful in
predicting carotid plaque instability.
Clinical lower extremity ischemia: A human model of ischemia
tolerance
Badhwar A, Forbes TL, Lovell MB. Can J Surg 2004;47:352-8.
Conclusion: Acute ischemia followed by reperfusion results in less
ischemic damage to muscle tissue in patients with chronic lower extremity
ischemia in comparison to patients without chronic lower extremity ischemia
prior to the acute ischemic insult.
Summary: Ischemic preconditioning has a protective effect against
future ischemic injury to muscle tissue. Some ischemia is unavoidable during
vascular surgical procedures involving arteries to the lower extremity. The
authors sought to determine whether there are different degrees of isch-
emia/reperfusion injury in patients undergoing vascular surgery for occlu-
sive disease vs aneurysm repair.
The authors studied three groups of patients from a university-affiliated
medical center. The first group (n 6) had chronic lower extremity ischemia
and were undergoing femoral distal bypass. Four patients (group 2) under-
went aortofemoral bypass for aortoiliac occlusive disease, and seven patients
underwent elective open repair of an infrarenal abdominal aortic aneurysm
and had no associated occlusive disease (group 3; control group). Three
hematologic indicators of skeletal muscle injury (creatine kinase [CK],
lactate dehydrogenase [LDH], and myoglobin) were measured immediately
prior to induction of surgical ischemia, during surgical ischemia, immedi-
ately upon reperfusion, 15 minutes after reperfusion, 1 hour after reperfu-
sion, and during the first, second, and third postoperative days.
Markers of skeletal injury at baseline were similar in all groups. Postre-
perfusion concentrations of markers of muscle injury were lower in the two
groups undergoing operation for occlusive disease than in the aneurysm
control group. At day 2, LDH levels were increased approximately 30% in
the aneurysm control group compared with the distal bypass and aortoiliac
occlusive disease groups (P  .05). Myoglobin increased 977% in the
aneurysm group but only 160% in the distal bypass group and 528% in the
aortobifemoral bypass group (P .01). CK levels were 1432% higher in the
aneurysm group, only 111% higher in the distal bypass group, and 120%
higher in the aortofemoral occlusive disease group (P  .05).
Comment: The author’s model is far from perfect. Patients undergo-
ing AAA repair have many more things rendered ischemic during aneurysm
repair than just leg muscles. AAA repair involves pelvic ischemia and likely
some degree of colon ischemia that does not occur during lower extremity
bypass. It is well recognized that patients with chronic lower extremity
ischemia tolerate acute occlusion better than patients without chronic
occlusive disease. However, this may be due to more extensive collateral
development in patients with chronic ischemia rather than ischemic precon-
ditioning of the muscle tissue itself.
Risk of myocardial infarction and stroke after acute infection or
vaccination
Smeeth L, Thomas SL, Hall HJ, et al. N Engl J Med 2004;351:2611-8.
Conclusion: Acute infections are associated with a temporary increase
in the risk of vascular events.
Summary: It is known that chronic infection may promote atheroscle-
rotic disease. The authors sought to examine whether a vaccination or acute
infection increases the short-term risk of cardiovascular events. A case-series
method was used to study within-person comparisons of risk of myocardial
infarction and stroke after naturally occurring infections and commonly used
vaccinations. Data were extracted from the general practice research data-
base of the United Kingdom. This database contains medical records of
more than 5 million patients.
The analysis included 19,063 patients with a first stroke who received
influenza vaccine and 20,484 persons with a first myocardial infarction.
There was no increase in the risk of stroke or myocardial infarction after
pneumococcal, tetanus, or influenza vaccine. Both stroke and myocardial
infarction were increased after a diagnosis of respiratory tract infection. Risks
were highest during the first 3 days (incident ratio for stroke, 3.19; 95% CI,
2.81-3.62; incident rate for myocardial infarction, 4.95; 95% CI, 4.3-5.53.)
Risk was also increased after urinary tract infection but was not as pro-
nounced as after upper respiratory tract infection.
Comment: This very large database supports a link between acute
infection and vascular events. It now needs to be established whether the risk
is due to alterations in red cell activation, dehydration, or perhaps the
institution of bed rest with the illness. The authors correctly point out that
the associated increased risk of cardiovascular events with infection in two
very different organ systems suggests the possibility of an underlying genetic
basis for this increased risk.
Different effects of anti-hypertensive regimens based on fosinopril or
hydrochlorothiazide with or without lipid lowering by pravastatin on
progression of asymptomatic carotid arthrosclerosis. Principal results
of PHYLLIS—A randomized double-blind trial
Zanchetti A, Crepaldi G, Bond MG, et al. Stroke 2004;35:2807-12.
Conclusion: Carotid atherosclerosis progression occurs with hydro-
chlorothiazide, but not with the ACE inhibitor fosinopril. Carotid athero-
sclerosis can also be prevented by the combination of pravastatin and
hydrochlorothiazide.
Summary: Patients with hypertension and hypercholesterolemia are at
risk for progression of carotid atherosclerosis. This study reports the result of
PHYLLIS (the plaque hypertension lipid-lowering Italian study). The study
was designed to test, in hypertensive patients with hypercholesterolemia and
asymptomatic atherosclerosis, (1) whether antihypertensive therapy with an
ACE inhibitor (fosinopril) was more effective in preventing the progression
of carotid atherosclerosis than antihypertensive therapy with hydrochlo-
rothiazide; (2) whether lipid lowering with pravastatin was more effective
than placebo when associated with either hydrochlorothiazide or fosinopril;
and (3) whether there were additive effects of lipid-lowering therapies and
ACE inhibitors on carotid atherosclerosis progression. Patients receiving
fosinopril received 20 g/d, those receiving hydrochlorothiazide received 25
mg/d, and the pravastatin dose was 40 mg/d.
There were 508 patients with hypercholesterolemia, hypertension, and
asymptomatic carotid stenosis randomized to (A) hydrochlorothiazide, (B)
fosinopril, (C) hydrochlorothiazide plus pravastatin, and (D) fosinopril plus
pravastatin. Follow-up was for 2.6 years, with the investigators blinded to
the drug. There were 13 centers involved. B-mode carotid duplex scans for
intima-medial thickness were performed at local centers and read centrally.
The primary end point was mean maximal intima-media thickness of the near
and far walls of the common carotid arteries and common carotid bifurca-
tions bilaterally (CBMmax).
CBMmax progressed significantly in group A (hydrochlorothiazide
alone) but not in groups B, C, or D (0.010  0.004 mm/y). Sites of
CBMmax changes in groups B, C, and D were different from those changes
in group A, with group A changes concentrated at the bifurcation. Blood
pressure reductions were not significantly different between groups, but
low-density and total lipoprotein cholesterol decreased by 1 mL/L in
groups C and D.
Comment: We are rapidly moving toward a “cocktail” of drugs for
patients with atherosclerosis or at risk of atherosclerosis. This study demon-
strates that an ACE inhibitor and a statin can inhibit progression of athero-
sclerosis at the carotid bifurcation. The effect of ACE inhibitors and statins
on cerebrovascular clinical events cannot be determined from this study.
Nevertheless, this is another bit of support for essentially routine use of a
statin, a -blocker, and now an ACE inhibitor in patients who are at
significant risk for progression of atherosclerosis.
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